GGrantIndex
← Leaderboards

Robert C Kalayjian

Case Western Reserve University

Google Scholar ↗PubMed ↗ORCID ↗
$157,708
Attributed
$157,708
Total exposure
17
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $59.2K · FY2005–06
$100K$75K$50K$25K$0
'05
'06

Funding mix

By agency

NIH$157,708 · 17

By mechanism

M01$157,708 · 17

Top collaborators

No co-investigators on record.

Most similar at Case Western Reserve University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectHuman Therapy EvaluationHiv InfectionsAids TherapyCombination ChemotherapyProtease InhibitorRitonavirAntiaids AgentReverse Transcriptase InhibitorsStavudineNevirapineNelfinavirLamivudinePatient Oriented ResearchHormone TherapyAntiviral AgentsCellular ImmunityEfavirenzHelper T LymphocyteHormone Regulation /Control MechanismLeukocyte CountPrednisoneZidovudine

Grant awards (30)

ACTG A5146: THERAPEUTIC DRUG MONITORING ON VIRAL LOAD, PI-EXPERIENCED HIV-1 PTS$27,014
M01 · FY2006 · RR · contact PI
A5211: AN ORALLY ADMINISTERED HIV-1 ENTRY INHIBITOR IN HIV TX EXPERIENCED PTS$14,151
M01 · FY2006 · RR · contact PI
A5214: SQ SINGLE DOSE INTERLEUKIN-7 IN HIV-1 INFECTED SUBJECTS$9,003
M01 · FY2006 · RR · contact PI
A5163: WEEKLY ALENDRONATE IN HIV SUBJECTS WITH DECREASED BONE MINERAL DENSITY$3,859
M01 · FY2006 · RR · contact PI
A5142:COMPARISON OF TREATMENT FOR INITIAL THERAPY OF HIV INFECTION$2,574
M01 · FY2006 · RR · contact PI
A5223: SEX DIFFERENCES IN LPV/RTV IN HIV INFECTED MEN AND WOMEN$2,574
M01 · FY2006 · RR · contact PI
ACTG A5163:QWEEK ALENDRONATE IN HIV SUBJECTS WITH DECREASED BONE MINERAL DENSITY$13,978
M01 · FY2005 · RR
ACTG A5177:PHARMACOKINETICS OF EFAVIRENZ, NEVIRAPINE, LOPINAVIR/RITONAVIR IN HIV$9,320
M01 · FY2005 · RR
ACTG A5142:COMPARISON OF TREATMENT FOR INITIAL THERAPY OF HIV INFECTION$5,825
M01 · FY2005 · RR
A5211: AN ORALLY ADMINISTERED HIV-1 ENTRY INHIBITOR IN HIV TX EXPERIENCED PTS$3,494
M01 · FY2005 · RR
ACTG A5143/A5147S: DUAL VS TRIPLE PI COMBINATIONS FOR TREATMENT FAILURES IN HIV1$2,773
M01 · FY2004 · RR
ACTG A5142-COMPARISON OF TREATMENT FOR INITIAL THERAPY OF HIV INFECTION$2,218
M01 · FY2004 · RR
ACTG A5110-THYMIDINE ANALOGUE SUBSTITUTION OR NUCLEOSIDE-SPARING REGIMEN$2,218
M01 · FY2004 · RR
ACTG A5163: WEEKLY ALENDRONATE IN HIV SUBJS WITH DECREASED BONE MINERAL DENSITY$556
M01 · FY2004 · RR
ACTG A5148: NIACIN FOR TREATMENT OF ELEVATED NON-HDL CHOLESTEROL IN HIV$554
M01 · FY2004 · RR
ABT378/ritonavir in combination with other drugs in HIV infection$0
M01 · FY2002 · RR
ABT378/ritonavir/stavudine/lamivudine/nelfinavir in HIV infection$0
M01 · FY2002 · RR
ACTG 349--Immunologic &virologic effects of prednisone on HIV-1 infection$0
M01 · FY2002 · RR
ACTG 384--Protease /reverse transcriptase inhib in HIV$0
M01 · FY2002 · RR
ACTG 349--Immunologic &virologic effects of prednisone on HIV-1 infection$0
M01 · FY2001 · RR
ABT378/ritonavir in combination with other drugs in HIV infection$0
M01 · FY2001 · RR
ABT378/ritonavir/stavudine/lamivudine/nelfinavir in HIV infection$0
M01 · FY2001 · RR
ACTG 384--Protease /reverse transcriptase inhib in HIV$0
M01 · FY2001 · RR
ACTG 359:SOFT GELATIN CAPSULE OF SAQUINAVIR W/ RITONAVIR OR NELFINAVI$19,199
M01 · FY2000 · RR
ACTG 370:VIROLOGIC &IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VS$19,199
M01 · FY2000 · RR
ACTG 372:PROLONGATION OF VIROLOGIC SUCCESS &OPTIONS FOR FAILURE IN H$19,199
M01 · FY2000 · RR
ACTG 384--Protease /reverse transcriptase inhib in HIV$0
M01 · FY2000 · RR
ACTG 349--Immunologic &virologic effects of prednisone on HIV-1 infection$0
M01 · FY2000 · RR
ABT378/ritonavir in combination with other drugs in HIV infection$0
M01 · FY2000 · RR
ABT378/ritonavir/stavudine/lamivudine/nelfinavir in HIV infection$0
M01 · FY2000 · RR